Motif Neurotech has secured clearance from the US Food and Drug Administration to begin its first clinical trial for its brain implant targeting treatment-resistant depression. The Digitally programmable Over-brain Therapeutic (DOT), delivers electrical stimulation to brain circuits linked to depression without penetrating brain tissue as it is placed in the skull.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever